News articles about Ophthotech (NASDAQ:OPHT) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ophthotech earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.7039574156356 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Ophthotech (NASDAQ:OPHT) opened at $2.85 on Friday. The company has a market cap of $100.55, a price-to-earnings ratio of 1.82 and a beta of 1.58. Ophthotech has a 1-year low of $2.24 and a 1-year high of $5.05.
A number of equities research analysts have recently issued reports on the stock. TheStreet raised shares of Ophthotech from an “e+” rating to a “c” rating in a research note on Thursday, November 30th. ValuEngine cut shares of Ophthotech from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Zacks Investment Research upgraded shares of Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price target for the company in a report on Monday, November 13th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $4.00 price target on shares of Ophthotech in a report on Thursday, September 21st.
In related news, insider David R. Guyer sold 16,520 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $3.19, for a total transaction of $52,698.80. Following the sale, the insider now directly owns 50,494 shares of the company’s stock, valued at approximately $161,075.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Glenn Sblendorio sold 8,089 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $3.19, for a total transaction of $25,803.91. Following the sale, the chief executive officer now directly owns 44,584 shares in the company, valued at approximately $142,222.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,971 shares of company stock valued at $111,481. 2.00% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Ophthotech (OPHT) Getting Somewhat Positive Press Coverage, Accern Reports” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/14/ophthotech-opht-earns-news-sentiment-score-of-0-12.html.
Ophthotech Company Profile
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.